Several research firms recently weighed in on STE. Morgan Stanley upped their price objective on shares of STERIS from $276.00 to $295.00 and gave the stock an "overweight" rating in a research report on Friday, August 8th. Citigroup reiterated an "outperform" rating on shares of STERIS in a research report on Friday, May 16th. Wall Street Zen upgraded shares of STERIS from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 9th. Jefferies Financial Group initiated coverage on shares of STERIS in a research report on Thursday, May 29th. They set a "hold" rating and a $263.00 price target on the stock. Finally, KeyCorp increased their price target on shares of STERIS from $277.00 to $288.00 and gave the company an "overweight" rating in a research report on Tuesday, July 22nd. Six analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock.